$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Analysis on whether you can stop taking venetoclax/venetoclax at will once you start taking it
2026-02-01 22:25:32
Check Details
How to purchase Asciminib and its channel description
2026-02-01 22:25:32
Check Details
Introduction to the countries and drug background of R&D and production of Ritlecitinib
2026-02-01 22:25:32
Check Details
Spasentan (sparsentan) adverse reactions and patient safety precautions
2026-02-01 22:25:32
Check Details
Introduction to Ixazomib manufacturers and drug quality and reliability
2026-02-01 22:25:32
Check Details
Is Lurbinectedin a domestic drug or an imported drug and how to purchase it
2026-02-01 22:25:32
Check Details
How effective is Doxorubicin treatment? Clinical response and efficacy assessment in cancer patients
2026-02-01 22:25:32
Check Details
How long should everolimus (Afinitor) be taken to see the therapeutic effect and treatment course recommendations?
2026-02-01 22:25:32
Check Details
Things to note and safety guidelines when taking estramustine (Adelox)
2026-02-01 22:25:32
Check Details
Whether drug resistance will occur after taking seripalase (BRINEURA) and strategies to deal with drug resistance
2026-02-01 22:25:32
Check Details
Detailed comparative analysis of the differences, advantages and disadvantages between Eslicarbazepine and Oxcarbazepine
2026-02-01 22:25:32
Check Details
Common side effects of Anagrelide and how to deal with adverse reactions
2026-02-01 22:25:32
Check Details
1
2
...
2164
2165
2166
2167
2168
2169
2170
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma